Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyung-Sang Yu

Showing results (101-110 of 349) with videos related to

Pageof 35
Sort By:
Translational and Clinical Pharmacology|February 15, 2020
Development of a physiologically-based pharmacokinetic model for cyclosporine in Asian children with renal impairmentSumin Yoon, Sojeong Yi, Su-Jin Rhee, et al.
Drug Design, Development and Therapy|August 24, 2019
Pharmacokinetics and tolerability of IDP-73152 mesylate after a single oral administration under fasted and fed conditions in healthy volunteersDongseong Shin, Sang-In Park, Hong-Sub Lee, et al.
Clinical Pharmacology in Drug Development|August 2, 2021
Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly SubjectsJoo Young Na, Inseung Jeon, Jangsoo Yoon, et al.
British Journal of Clinical Pharmacology|April 23, 2002
Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19Joo-Youn Cho, Kyung-Sang Yu, In-Jin Jang, et al.
Clinical Pharmacology and Therapeutics|September 7, 2017
Identification of ω- or (ω-1)-Hydroxylated Medium-Chain Acylcarnitines as Novel Urinary Biomarkers for CYP3A ActivityBora Kim, Jieon Lee, Kwang-Hee Shin, et al.
Clinical Therapeutics|November 25, 2010
Pharmacokinetic and pharmacodynamic comparison of two recombinant human erythropoietin formulations after single subcutaneous administration: an open-label, sequence-randomized, two-treatment crossover study in healthy Korean male volunteersTae-Eun Kim, Kyu-Pyo Kim, Bo-Hyung Kim, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 3, 2003
Sensitive liquid chromatography assay with ultraviolet detection for a new phosphodiesterase V inhibitor, DA-8159, in human plasma and urineJoo Youn Cho, Hyeong Seok Lim, Kyung Sang Yu, et al.
Clinical Therapeutics|November 18, 2011
Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteersNamyi Gu, Sojeong Yi, Tae-Eun Kim, et al.
Translational and Clinical Pharmacology|February 15, 2020
Pharmacokinetics of fixed-dose combination of rosuvastatin 20 mg and ezetimibe 10 mg compared to concurrent administration of individual tablets in healthy Korean subjectsInyoung Hwang, Sang-In Park, SeungHwan Lee, et al.
Alimentary Pharmacology & Therapeutics|October 28, 2020
Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicitiesJun Gi Hwang, Inseung Jeon, Sun Ae Park, et al.
Pageof 35

Showing results (101-110 of 349) with videos related to

Sort By:
Pageof 35
Translational and Clinical Pharmacology|February 15, 2020
Development of a physiologically-based pharmacokinetic model for cyclosporine in Asian children with renal impairmentSumin Yoon, Sojeong Yi, Su-Jin Rhee, et al.
Drug Design, Development and Therapy|August 24, 2019
Pharmacokinetics and tolerability of IDP-73152 mesylate after a single oral administration under fasted and fed conditions in healthy volunteersDongseong Shin, Sang-In Park, Hong-Sub Lee, et al.
Clinical Pharmacology in Drug Development|August 2, 2021
Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly SubjectsJoo Young Na, Inseung Jeon, Jangsoo Yoon, et al.
British Journal of Clinical Pharmacology|April 23, 2002
Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19Joo-Youn Cho, Kyung-Sang Yu, In-Jin Jang, et al.
Clinical Pharmacology and Therapeutics|September 7, 2017
Identification of ω- or (ω-1)-Hydroxylated Medium-Chain Acylcarnitines as Novel Urinary Biomarkers for CYP3A ActivityBora Kim, Jieon Lee, Kwang-Hee Shin, et al.
Clinical Therapeutics|November 25, 2010
Pharmacokinetic and pharmacodynamic comparison of two recombinant human erythropoietin formulations after single subcutaneous administration: an open-label, sequence-randomized, two-treatment crossover study in healthy Korean male volunteersTae-Eun Kim, Kyu-Pyo Kim, Bo-Hyung Kim, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|October 3, 2003
Sensitive liquid chromatography assay with ultraviolet detection for a new phosphodiesterase V inhibitor, DA-8159, in human plasma and urineJoo Youn Cho, Hyeong Seok Lim, Kyung Sang Yu, et al.
Clinical Therapeutics|November 18, 2011
Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteersNamyi Gu, Sojeong Yi, Tae-Eun Kim, et al.
Translational and Clinical Pharmacology|February 15, 2020
Pharmacokinetics of fixed-dose combination of rosuvastatin 20 mg and ezetimibe 10 mg compared to concurrent administration of individual tablets in healthy Korean subjectsInyoung Hwang, Sang-In Park, SeungHwan Lee, et al.
Alimentary Pharmacology & Therapeutics|October 28, 2020
Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicitiesJun Gi Hwang, Inseung Jeon, Sun Ae Park, et al.
Pageof 35